Indications and efficacy of continuous subcutaneous insulin infusion (CSII) therapy in Type 1 diabetes mellitus: a clinical audit in a specialist service
- 23 June 2005
- journal article
- Published by Wiley in Diabetic Medicine
- Vol. 22 (7), 842-849
- https://doi.org/10.1111/j.1464-5491.2005.01539.x
Abstract
To determine if current guidelines correctly identify patients who will benefit from continuous subcutaneous insulin infusion (CSII) therapy by comparing outcomes between Type 1 diabetic patients with recurrent severe hypoglycaemia (SH) indications with those without; and between patients without and with classic contraindications to CSII managed in a single multidisciplinary pump clinic. Changes in biomedical outcomes [glycated haemoglobin (HbA1c), hypoglycaemia, diabetic ketoacidosis (DKA) rates], from before CSII to the end of the study (median duration 20.5 months, range 1-192), were analysed retrospectively from data collected from notes and interviews of 40 patients. Quality of life was assessed by three validated questionnaires at study end (33 patients). Twenty-five out of forty patients were started for reasons other than SH and 15 out of 40 had contraindications to CSII. Overall, CSII was associated with a reduction in HbA1c (9.6 +/- 2.7% to 8.3 +/- 1.2%, P = 0.011), SH (6.45 +/- 16.15/year to 0.34 +/- 1.01/year, P = 0.034) and DKA (1.83 +/- 4.48/year to 0.27 +/- 1.12/year, P = 0.036). The fall in SH was greater for patients started for SH (P < 0.001). However, only patients started for other indications showed a fall in HbA1c (P = 0.001). The fall in DKA rate was greater in patients with contraindications (P = 0.042), and they did not lose the other benefits of CSII therapy, including quality of life. In the setting of a specialist multidisciplinary service, CSII can be an effective and safe therapy. It confers benefit outside the setting of severe hypoglycaemia and can confer benefit in some patients with classic contraindications. This questions the validity of criteria that may exclude these patients in such a service.Keywords
This publication has 24 references indexed in Scilit:
- Insulin Pump Therapy in Patients with Type 1 Diabetes Mellitus: Results of the Nationwide Quality Circle in Germany (ASD) 1999 - 2000Experimental and Clinical Endocrinology & Diabetes, 2003
- Continuous Subcutaneous Insulin InfusionDiabetes Care, 2003
- Protocol for Outpatient Screening and Initiation of Continuous Subcutaneous Insulin Infusion Therapy: Impact on Cost and QualityThe Diabetes Educator, 2002
- How Diabetes Specialists Treat Their Own Diabetes: Findings From a Study of the AADE and ADA MembershipThe Diabetes Educator, 2000
- Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I DiabetesDiabetes Care, 1996
- The rand 36‐item health survey 1.0Health Economics, 1993
- Reliability and Validity of a Diabetes Quality-of-Life Measure for the Diabetes Control and Complications Trial (DCCT)Diabetes Care, 1988
- Psychological Considerations for Patient Selection and Adjustment to Insulin Pump TherapyThe Diabetes Educator, 1988
- A randomized clinical trial of the insulin pump vs intensive conventional therapy in diabetic pregnanciesJAMA, 1986
- Rarity of a Marked “Dawn Phenomenon” in Diabetic Subjects Treated by Continuous Subcutaneous Insulin InfusionDiabetes Care, 1985